Literature DB >> 28496672

The Power of One: a Highly Detailed, Log-Based, Case Example that Clearly Demonstrates the Effective Use of Ranolazine for the Control of Progressive Atrial Fibrillationn.

James A Reiffel1.   

Abstract

Entities:  

Year:  2010        PMID： 28496672      PMCID： PMC4955906          DOI： 10.4022/jafib.304

Source DB:  PubMed          Journal:  J Atr Fibrillation        ISSN： 1941-6911


× No keyword cloud information.
  10 in total

1.  Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current.

Authors:  Albertas I Undrovinas; Luiz Belardinelli; Nidas A Undrovinas; Hani N Sabbah
Journal:  J Cardiovasc Electrophysiol       Date:  2006-05

2.  ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation).

Authors:  Valentin Fuster; Lars E Rydén; David S Cannom; Harry J Crijns; Anne B Curtis; Kenneth A Ellenbogen; Jonathan L Halperin; Jean-Yves Le Heuzey; G Neal Kay; James E Lowe; S Bertil Olsson; Eric N Prystowsky; Juan Luis Tamargo; Samuel Wann
Journal:  Eur Heart J       Date:  2006-08       Impact factor: 29.983

3.  Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes.

Authors:  Yejia Song; John C Shryock; Lin Wu; Luiz Belardinelli
Journal:  J Cardiovasc Pharmacol       Date:  2004-08       Impact factor: 3.105

4.  The effect of ranolazine on maintaining sinus rhythm in patients with resistant atrial fibrillation.

Authors:  David K Murdock; Naomi Overton; Mary Kersten; Jeff Kaliebe; Fausto Devecchi
Journal:  Indian Pacing Electrophysiol J       Date:  2008-08-01

5.  Effect of dronedarone on cardiovascular events in atrial fibrillation.

Authors:  Stefan H Hohnloser; Harry J G M Crijns; Martin van Eickels; Christophe Gaudin; Richard L Page; Christian Torp-Pedersen; Stuart J Connolly
Journal:  N Engl J Med       Date:  2009-02-12       Impact factor: 91.245

6.  The use of oral ranolazine to convert new or paroxysmal atrial fibrillation: a review of experience with implications for possible "pill in the pocket" approach to atrial fibrillation.

Authors:  David K Murdock; Mary Kersten; Jeff Kaliebe; German Larrain
Journal:  Indian Pacing Electrophysiol J       Date:  2009-09-01

7.  Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial.

Authors:  David A Morrow; Benjamin M Scirica; Ewa Karwatowska-Prokopczuk; Sabina A Murphy; Andrzej Budaj; Sergei Varshavsky; Andrew A Wolff; Allan Skene; Carolyn H McCabe; Eugene Braunwald
Journal:  JAMA       Date:  2007-04-25       Impact factor: 56.272

8.  Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial.

Authors:  Benjamin M Scirica; David A Morrow; Hanoch Hod; Sabina A Murphy; Luiz Belardinelli; Chester M Hedgepeth; Peter Molhoek; Freek W A Verheugt; Bernard J Gersh; Carolyn H McCabe; Eugene Braunwald
Journal:  Circulation       Date:  2007-09-05       Impact factor: 29.690

9.  Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine.

Authors:  Alexander Burashnikov; José M Di Diego; Andrew C Zygmunt; Luiz Belardinelli; Charles Antzelevitch
Journal:  Circulation       Date:  2007-09-04       Impact factor: 29.690

10.  Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties.

Authors:  Charles Antzelevitch; Luiz Belardinelli; Andrew C Zygmunt; Alexander Burashnikov; José M Di Diego; Jeffrey M Fish; Jonathan M Cordeiro; George Thomas
Journal:  Circulation       Date:  2004-08-09       Impact factor: 29.690
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.